220 related articles for article (PubMed ID: 32479916)
1. Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence.
Duskey JT; Ottonelli I; Da Ros F; Vilella A; Zoli M; Kovachka S; Spyrakis F; Vandelli MA; Tosi G; Ruozi B
Nanomedicine; 2020 Aug; 28():102226. PubMed ID: 32479916
[TBL] [Abstract][Full Text] [Related]
2. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
3. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
4. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
5. Targeting specific cells in the brain with nanomedicines for CNS therapies.
Zhang F; Lin YA; Kannan S; Kannan RM
J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
7. Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.
Vilella A; Ruozi B; Belletti D; Pederzoli F; Galliani M; Semeghini V; Forni F; Zoli M; Vandelli MA; Tosi G
Pharmaceutics; 2015 Jun; 7(2):74-89. PubMed ID: 26102358
[TBL] [Abstract][Full Text] [Related]
8. Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation.
May JN; Golombek SK; Baues M; Dasgupta A; Drude N; Rix A; Rommel D; von Stillfried S; Appold L; Pola R; Pechar M; van Bloois L; Storm G; Kuehne AJC; Gremse F; Theek B; Kiessling F; Lammers T
Theranostics; 2020; 10(4):1948-1959. PubMed ID: 32042346
[No Abstract] [Full Text] [Related]
9. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
Tam VH; Sosa C; Liu R; Yao N; Priestley RD
Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
[TBL] [Abstract][Full Text] [Related]
11. Polymersomes conjugated with des-octanoyl ghrelin for the delivery of therapeutic and imaging agents into brain tissues.
Chen YC; Chiang CF; Chen LF; Liao SC; Hsieh WY; Lin WL
Biomaterials; 2014 Feb; 35(6):2051-65. PubMed ID: 24315575
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
13. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.
Tosi G; Vilella A; Veratti P; Belletti D; Pederzoli F; Ruozi B; Vandelli MA; Zoli M; Forni F
Mol Pharm; 2015 Oct; 12(10):3672-84. PubMed ID: 26312414
[TBL] [Abstract][Full Text] [Related]
14. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy.
van den Broek SL; Shalgunov V; Herth MM
Biomater Adv; 2022 Oct; 141():213125. PubMed ID: 36182833
[TBL] [Abstract][Full Text] [Related]
15. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
16. Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood-Brain Barrier Both in Vitro and in Vivo.
Aparicio-Blanco J; Romero IA; Male DK; Slowing K; García-García L; Torres-Suárez AI
Mol Pharm; 2019 May; 16(5):1999-2010. PubMed ID: 30865462
[TBL] [Abstract][Full Text] [Related]
17. Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier.
Nafee N; Gouda N
Curr Gene Ther; 2017; 17(2):154-169. PubMed ID: 28494740
[TBL] [Abstract][Full Text] [Related]
18. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
Costantino L; Gandolfi F; Tosi G; Rivasi F; Vandelli MA; Forni F
J Control Release; 2005 Nov; 108(1):84-96. PubMed ID: 16154222
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier.
Tosi G; Duskey JT; Kreuter J
Expert Opin Drug Deliv; 2020 Jan; 17(1):23-32. PubMed ID: 31774000
[No Abstract] [Full Text] [Related]
20. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
